Sign In
Buy FOLD
$14.49
+0 (+0%)
At Close: Jun 03, 2026
U.S. Supreme Court Decision Cites NCLA's Amicus Brief in Preserving Access to Federal Courts
05:03pm, Friday, 20'th Jun 2025
Food and Drug Administration; et al. v. R.J. Reynolds Vapor Company; RJR Vapor Company L.L.C.; Avail Vapor Texas, L.L.C.; and Mississippi Petroleum Marketers and Convenience Stores Association Food an
Physician group filed an amicus brief in Chiles v. Salazar defending the right of licensed therapists to offer "conversion therapy" in gender dysphoria.
In NCLA Amicus Win, Supreme Court Revives Innocent Family's Suit over FBI's Wrong-House Raid
06:23pm, Friday, 13'th Jun 2025
Washington, DC, June 13, 2025 (GLOBE NEWSWIRE) -- The U.S. Supreme Court unanimously reversed the Eleventh U.S. Circuit Court of Appeals' dismissal of Martin v. United States, an Atlanta family's Fede
In NCLA Amicus Win, District Court Topples Kansas Dog Kennel No-Warrant Inspection Regime
04:16pm, Thursday, 12'th Jun 2025
Scott Johnson, Harlene Hoyt, Covey Find Kennel, LLC v. Justin Smith, D.V.M., in his official capacity as Animal Health Commissioner at the Kansas Department of Agriculture Scott Johnson, Harlene Hoyt,
Amicus Therapeutics: Opportunity Awaits In This Beaten Down Pharma
10:14am, Thursday, 12'th Jun 2025
Amicus Therapeutics is a commercial-stage biotech with a focused pipeline in Fabry, Pompe, and rare kidney diseases. Galafold, its lead therapy, is the only approved oral treatment for Fabry disease a
New Strong Sell Stocks for June 3rd
08:46am, Tuesday, 03'rd Jun 2025
FOLD, BRCC and VLVLY have been added to the Zacks Rank #5 (Strong Sell) List on May 3, 2025.
New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve
07:00am, Tuesday, 03'rd Jun 2025
PRINCETON, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the publication of a post-hoc analysis of data from the ERT-experienced cohort of the PROPEL stud
Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025
07:00am, Friday, 30'th May 2025
PRINCETON, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in
Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference
07:00am, Wednesday, 07'th May 2025
PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Bank of America 2025 Health Care Confere
FOLD Q1 Earnings and Sales Miss Estimates, Stock Falls
02:20pm, Friday, 02'nd May 2025
Amicus' first-quarter 2025 earnings and sales miss estimates. Shares decline.
Amicus Therapeutics, Inc. (FOLD) Q1 2025 Earnings Call Transcript
04:24pm, Thursday, 01'st May 2025
Amicus Therapeutics, Inc. (NASDAQ:FOLD ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Andrew Faughnan - Vice President of Investor Relations Bradley Campbell - Presiden
Amicus Therapeutics (FOLD) Q1 Earnings and Revenues Lag Estimates
09:15am, Thursday, 01'st May 2025
Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.02 per share a year ago.
Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates
07:00am, Thursday, 01'st May 2025
1Q 2025 Total Revenue of $125.2M, a 15% Increase Year-over-Year at CER Expanding Portfolio through In-Licensing of DMX-200 Phase 3 Program for Rare Kidney Disease with Significant Market Potential in
Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States
07:12pm, Wednesday, 30'th Apr 2025
Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS)
Amicus Therapeutics (FOLD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:09am, Thursday, 24'th Apr 2025
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
